Short-term Haematological and Biochemical Safety of Lu-177 DOTATATE Therapy

被引：0
|
作者：
Kauppila, E. [2 ]
Allen, R. [1 ]
Ifigeneia, K. [1 ]
Meades, R. [1 ]
Tan, T. [1 ]
Barwick, T. [1 ]
Soneji, N. [1 ]
Al-Nahhas, A. [1 ]
Win, Z. [1 ]
机构：
[1] Imperial Healthcare NHS Trust, London, England
[2] Univ Eastern Finlan, Kuopio, Finland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P1033
引用
收藏
页码：S587 / S587
页数：1
相关论文
共 50 条
  • [21] Optimisation of Lu-177 therapy administration
    Fernandez, R.
    Rai, S.
    Perry, A.
    Johnson, J.
    Croasdale, P.
    Eftychiou, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S661 - S662
  • [22] RELATIONSHIP BETWEEN WHOLE BODY CLEARANCE, KIDNEY DOSE AND GFR IN [LU-177]-DOTATATE THERAPY
    Hennessy, T.
    Bailey, D.
    Willowson, K.
    Chan, D.
    Pavlakis, N.
    Schembri, G.
    Roach, P.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 18 - 19
  • [23] Evaluation of thyroid function in patients receiving Lu-177 DOTATATE treatment
    Kibar, A.
    Ince, B.
    Nazari, A.
    Toplutas, K. N.
    Bilgic, S.
    Asa, S.
    Besli, R. L. Uslu
    Sager, M. S.
    Sayman, H. B.
    Sonmezoglu, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S470 - S470
  • [24] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [25] Lu-177 DOTATATE dosimetry for neuroendocrine tumor: single center experience
    Said, M. A.
    Masud, M. A.
    Zaini, M. Z.
    Salleh, R. A.
    Lee, B. N.
    Zainon, R.
    10TH INTERNATIONAL SEMINAR ON MEDICAL PHYSICS & 1ST AMDI INTERNATIONAL ONCOLOGY SYMPOSIUM, 2017, 851
  • [26] A Personalized Remote Radiation-Tracking Vest for At-Home Monitoring of LU-177 DOTATATE Therapy
    Pierce, Larry
    Harrison, Robert
    Vesselle, Hubert
    Miyaoka, Robert
    PANCREAS, 2020, 49 (03) : 483 - 483
  • [27] Assessment of Thyroid and Breast Radiation Absorbed Doses in Lu-177 DOTATATE Therapy Using Voxel Dosimetry
    Alandnosi, Fyrooz
    Alrasheedi, Mohammed
    Brady, Amy
    George, Remo
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [28] Short-term tolerability and dose toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors (NET)
    Plaza, Bonilla J.
    Lorca, Martinez A.
    Martinez, Navarro T.
    Hernandez, Azpeitia P.
    Alonso-Gordoa, T.
    Molina-Cerrillo, J.
    Diez, Orduna M. D. P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 137 - 137
  • [29] Evaluation of infusion pump delivery system for LUTATHERA® (lutetium Lu-177 dotatate).
    Doherty, Kathryn
    Houston, Tim
    Kowalczyk, Steven
    Gruchot, Michelle
    Dillehay, Gary
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [30] Comparative Dosimetric Evaluation on the course of PRRT using non carrier added LU-177 DOTATATE (i.a., i.v), non carrier added LU-177 DOTATOC (i.v.) and carrier added LU-177 DOTATATE (i.v.)
    Paphiti, M.
    McCready, R. V.
    Dimitriadi, E. Z.
    Limouris, G. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S190 - S191
12345